Vanda Pharmaceuticals IncNASDAQ:VNDA
- LAST PRICE4.8300
- TODAY'S CHANGE (%)0.0900 (1.8987%)
- Bid / Lots4.8300/ 2
- Ask / Lots4.8400/ 6
- Open / Previous Close4.8200 / 4.7400
- Day Range
- 52 Week Range
- Volume95,223
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VNDA |
|---|---|---|
| 09:32 ET | 5235 | 4.76 |
| 09:34 ET | 300 | 4.785 |
| 09:36 ET | 2295 | 4.74 |
| 09:38 ET | 600 | 4.76 |
| 09:39 ET | 100 | 4.76 |
| 09:41 ET | 600 | 4.78 |
| 09:45 ET | 5400 | 4.77 |
| 09:48 ET | 300 | 4.78 |
| 09:50 ET | 461 | 4.785 |
| 09:54 ET | 500 | 4.769 |
| 09:56 ET | 1845 | 4.77 |
| 09:57 ET | 728 | 4.78 |
| 10:01 ET | 200 | 4.785 |
| 10:06 ET | 1094 | 4.785 |
| 10:08 ET | 100 | 4.785 |
| 10:10 ET | 455 | 4.79 |
| 10:12 ET | 1333 | 4.7898 |
| 10:14 ET | 1251 | 4.79 |
| 10:15 ET | 700 | 4.78 |
| 10:17 ET | 9618 | 4.755 |
| 10:19 ET | 195 | 4.75 |
| 10:21 ET | 1945 | 4.745 |
| 10:24 ET | 200 | 4.745 |
| 10:26 ET | 1887 | 4.75 |
| 10:30 ET | 200 | 4.755 |
| 10:32 ET | 100 | 4.755 |
| 10:33 ET | 1975 | 4.74 |
| 10:35 ET | 765 | 4.76 |
| 10:37 ET | 100 | 4.765 |
| 10:39 ET | 11951 | 4.7999 |
| 10:42 ET | 16577 | 4.805 |
| 10:44 ET | 11177 | 4.83 |
Today
Yesterday
Vanda Pharmaceuticals Inc. Being Investigated on Behalf of Vanda Pharmaceuticals Inc. Investors. Contact Levi & Korsinsky For Details., from 7:27AM ET on Thursday Sep 26, 2024 by Dow Jones
7:27AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 25, 2024
Sep 24, 2024
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Vanda Pharmaceuticals Inc. (VNDA), from 7:31AM ET on Tuesday Sep 24, 2024 by Dow Jones
7:31AM ET on Tuesday Sep 24, 2024 by Dow Jones
Sep 23, 2024
Vanda Pharmaceuticals Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VNDA, from 7:22AM ET on Monday Sep 23, 2024 by Dow Jones
7:22AM ET on Monday Sep 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vanda Pharmaceuticals Inc | 276.3M | -25.6x | -37.98% |
Akebia Therapeutics Inc | 279.7M | -6.5x | --- |
Sangamo Therapeutics Inc | 175.8M | -0.6x | --- |
Sutro Biopharma Inc | 285.2M | -1.9x | --- |
Kamada Ltd | 308.7M | 18.4x | -22.48% |
Agenus Inc | 111.5M | -0.5x | --- |
Company Information
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Contact Information
- Headquarters
- SUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON, DC, United States 20037
- Phone
- 202-734-3400
- Fax
- 202-296-1450
Executives
- Chairman of the Board, President, Chief Executive Officer
- Mihael Polymeropoulos
- Chief Financial Officer, Senior Vice President, Treasurer
- Kevin Moran
- Senior Vice President, Chief Marketing Officer
- Joakim Wijkstrom
- Senior Vice President, General Counsel, Secretary
- Timothy Williams
- Senior Vice President - Business Development
- Gunther Birznieks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $276.3M |
|---|---|
Revenue (TTM) | $182.0M |
Shares Outstanding | 58.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-0.19 |
Book Value | $9.47 |
P/E Ratio | -25.6x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -17.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
